Über das Unternehmen
- Firmenname (rechtlich): Nanjing Hanxin Pharmaceutical Technology Co.,Ltd
- Registrierungsland: China
- Adresse: Building C5, No.9 Weidi Road, Xianlin Street, Qixia District, Nanjing, Jiangsu, China
- Gründungsjahr: 2021
Beschreibung:
Nanjing Hanxin Pharmaceutical Technology Co., Ltd, established in 2017, manufactures active pharmaceutical ingredients, digestive-system drugs, and peptides. The company was recognized as a Jiangsu Provincial Technology-Advanced Service Enterprise in 2019, obtained national-level intellectual property management system certification in 2020, acquired Nanjing Cuccess Pharmaceutical Co., Ltd. and earned National High-tech Enterprise status in 2021, and was designated a Jiangsu Provincial Specialized, Refined, Differential, and Innovative SME in 2022. Offering CRO, CMO, and CDMO contract manufacturing with OEM, ODM, and own-brand production, the company distributes to markets across North America, Central/South America, Western and Eastern Europe, Australasia, Asia, the Middle East, and Africa.
Geschäftsaktivitäten
Pharmazeutische Wirkstoffe (API)
API-HerstellerHersteller
Vertrags- & Outsourcing-Dienstleistungen
Auftragsentwicklungs- und Herstellungsorganisation (CDMO)
Absatzmärkte
- Western Europe: Austria, Belgium, France
- Northern America: Bermuda, Canada, Greenland, Saint Pierre and Miquelon, United States
- Central America: Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama
- South America: Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Falkland Islands, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela
Hauptprodukte/-dienstleistungen
- Pharmazeutische Wirkstoffe (API): Semaglutide, PDRN, Earthworm Protein, Chondroitin sulfate oligosaccharides (LetopCS) ® ）, GABA（ γ- Aminobutyric acid, Ergothione, Acetic acid ganerik (chemical synthesis), Acetylated sodium hyaluronate, Cationic sodium hyaluronate, Chloroacetyl catechol, DeGu insulin side chain, Epinephrine (chemical synthesis), Liraglutide 31 peptide main chain, Liraglutide (recombinant), NmHA ® Nano sodium hyaluronate, Norepinephrine bitartrate (chemically synthesized), Recombinant CPB, Recombinant EK, Recombinant Kex II, Recombinant type III collagen protein, Smegglutide 29 peptide main chain, Smegglutide side chain
- Naturextrakte & Pflanzliche Rohstoffe: Animal extracts
- Biologische & Fermentationsrohstoffe: Biological fermentation raw materials
- ATC-Klassifikation (Anatomisch-Therapeutisch-Chemisch): Insulin Aspart
Unsere Produkte & Dienstleistungen
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Certifications
FDA
GMP Formulation Facility
FDA- and GMP-compliant manufacturing site producing injectables
FDA inspections with zero Form 483 observations
FDA approval for oncology
Bewertungen
(0)
(0)
(0)
(0)
(0)
Kommentare
Filter:
Sortieren nach:
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen